Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

GLTO

Galecto Inc

Apr 22 • 04:00PM ET

0.6810

Dollar change -0.0005
Percentage change -0.07	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF IWC

Index	-	P/E	-	EPS (ttm)	-1.45	Insider Own	25.51%	Shs Outstand	27.11M	Perf Week	-0.92%
Market Cap	18.46M	Forward P/E	-	EPS next Y	-0.87	Insider Trans	0.00%	Shs Float	20.20M	Perf Month	-11.10%
Income	-38.35M	PEG	-	EPS next Q	-0.41	Inst Own	5.20%	Short Float	0.16%	Perf Quarter	3.34%
Sales	0.00M	P/S	-	EPS this Y	27.56%	Inst Trans	0.53%	Short Ratio	0.14	Perf Half Y	13.86%
Book/sh	1.19	P/B	0.57	EPS next Y	23.01%	ROA	-68.84%	Short Interest	0.03M	Perf Year	-66.78%
Cash/sh	1.22	P/C	0.56	EPS next 5Y	47.60%	ROE	-81.52%	52W Range	0.50 - 3.70	Perf YTD	-5.42%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-14.07%	ROI	-118.37%	52W High	-81.59%	Beta	1.26
Dividend TTM	-	Quick Ratio	6.31	Sales past 5Y	0.00%	Gross Margin	-	52W Low	36.20%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	6.31	EPS Y/Y TTM	40.13%	Oper. Margin	0.00%	RSI (14)	43.62	Volatility	6.79% 8.62%
Employees	13	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	2.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	56.49%	Payout	-	Rel Volume	0.27	Prev Close	0.68
Sales Surprise	-	EPS Surprise	30.12%	Sales Q/Q	-	Earnings	-	Avg Volume	225.77K	Price	0.68
SMA20	-6.13%	SMA50	-7.22%	SMA200	-27.01%	Trades		Volume	61,112	Change	-0.07%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-26-21	Resumed	Credit Suisse	Outperform	$12
Nov-23-20	Initiated	SVB Leerink	Outperform	$27
Nov-23-20	Initiated	Credit Suisse	Outperform	$29
Nov-23-20	Initiated	BofA Securities	Buy	$21

Mar-15-24 01:53PM	GLTO Stock Earnings: Galecto Beats EPS for Q4 2023 (InvestorPlace) +5.30%
Feb-14-24 12:00PM	Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +11.93%
Jan-09-24 04:57PM	What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock (Zacks)
Dec-22-23 06:52AM	Galecto posts myelofibrosis data as search for savior continues, investors shrug (FierceBiotech.com)
Dec-21-23 04:05PM	Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis (GlobeNewswire)
08:00AM	Loading…
Oct-23-23 08:00AM	Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial (GlobeNewswire)
Sep-28-23 09:49AM	Spotify downgraded, Tractor Supply upgraded: Wall Street's top analyst calls (The Fly)
Sep-27-23 05:08AM	Galecto lays off 70%, hunts for 'strategic alternatives' in wake of fibrosis drug fail (FierceBiotech.com) +22.24%
Sep-26-23 04:01PM	Galecto Announces Plans to Explore Strategic Alternatives (GlobeNewswire)
Aug-31-23 11:00AM	Galecto to Present at Investor Conferences in September (GlobeNewswire)
Aug-17-23 07:01PM	OrbiMed Advisors LLC Reduces Stake in Galecto Inc (GuruFocus.com)
08:58AM	Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More (Zacks)
Aug-16-23 07:46AM	Galecto (GLTO) Down 71% as Lung Disease Candidate Fails (Zacks)
Aug-15-23 07:35AM	Galecto to discontinue development of lung disease treatment (Reuters) -71.22%
07:30AM	Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
04:05PM	Loading…
Jul-31-23 04:05PM	Galecto Reports Second Quarter Operating and Financial Results (GlobeNewswire)
Jul-27-23 11:02PM	ORBIMED ADVISORS LLC Reduces Stake in Galecto Inc (GuruFocus.com)
Jul-25-23 09:59AM	These 2 Strong Buy Penny Stocks Could Go Boom, Say Analysts (TipRanks) +29.79%
Jun-20-23 08:58AM	Galecto Set to Join Russell Microcap® Index (GlobeNewswire)
May-30-23 08:00AM	Galecto to Present at the Upcoming Jefferies Healthcare Conference (GlobeNewswire)
May-23-23 08:30AM	Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
May-20-23 08:54AM	Companies Like Galecto (NASDAQ:GLTO) Could Be Quite Risky (Simply Wall St.)
May-17-23 04:01PM	Galecto to Present Poster at Upcoming ATS 2023 International Conference (GlobeNewswire)
Apr-28-23 08:00AM	Galecto Reports First Quarter Operating and Financial Results (GlobeNewswire)
Apr-13-23 08:30AM	Galecto to Present Two Posters at AACR Annual Meeting 2023 (GlobeNewswire)
Mar-09-23 07:00AM	Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022 (GlobeNewswire) -8.13%
Mar-02-23 04:05PM	Galecto to Participate in Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-01-23 08:00AM	Galecto to Participate in SVB Securities Global Biopharma Conference (GlobeNewswire) +5.65%
Dec-11-22 07:36AM	Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth? (Simply Wall St.)
Dec-07-22 04:05PM	Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
09:55AM	Loading…
Nov-24-22 09:55AM	Galecto, Inc. (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-11-22 12:00PM	All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy (Zacks)
Nov-08-22 09:15AM	Galecto Reports Third Quarter Operating and Financial Results (GlobeNewswire) -7.35%
06:00AM	Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients (GlobeNewswire)
Nov-03-22 08:00AM	Galecto to Participate in Jefferies London Healthcare Conference (GlobeNewswire) +20.01%
Oct-31-22 08:00AM	Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLDs The Liver Meeting® 2022 (GlobeNewswire) +6.35%
Oct-19-22 08:00AM	Galectos Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute (GlobeNewswire)
Oct-17-22 06:00AM	Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022 (GlobeNewswire)
Sep-29-22 11:17AM	Galecto's Myelofibrosis Candidate Reduces Bone Marrow Fibrosis (Benzinga) -22.08%
06:00AM	GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target (GlobeNewswire)
Sep-06-22 08:30AM	Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-29-22 08:30AM	Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal (GlobeNewswire)
Jul-29-22 09:00AM	Galecto Reports Second Quarter Operating and Financial Results (GlobeNewswire)
Jul-03-22 08:17AM	Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely? (Simply Wall St.)
Jun-16-22 08:00AM	Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC (GlobeNewswire)
May-31-22 08:30AM	Galecto to Participate at Jefferies Healthcare Conference (GlobeNewswire)
May-26-22 08:30AM	Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting (GlobeNewswire)
May-02-22 08:30AM	Galecto to Participate at Upcoming Investor Conferences (GlobeNewswire)
Apr-29-22 08:57AM	Galecto Reports First Quarter Operating and Financial Results (GlobeNewswire)
Apr-26-22 08:30AM	Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF (GlobeNewswire) -7.94%
Mar-29-22 08:30AM	Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis (GlobeNewswire)
Mar-25-22 10:25AM	UnitedHealth (UNH) Arm Optum Acquires Refresh Mental Health (Zacks)
Mar-15-22 11:10AM	Ensign Group (ENSG) Up 9.9% in 3 Months: More Room to Grow? (Zacks)
Mar-10-22 11:05AM	Here's Why You Should Retain Community Health (CYH) Stock (Zacks)
Mar-09-22 10:49AM	Anthem (ANTM) Rises 3.7% Since Q4 Earnings, Reiterates View (Zacks) +7.49%
Mar-04-22 10:00AM	Galecto, Inc. (GLTO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Feb-17-22 05:00PM	Galecto Reports Financial Results for the Year Ended December 31, 2021 (GlobeNewswire) -5.48%
Feb-07-22 08:00AM	Galecto to Participate at Upcoming Investor Conferences (GlobeNewswire)
Jan-27-22 07:00AM	Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care (GlobeNewswire)
Jan-24-22 05:56AM	Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth? (Simply Wall St.) +6.13%
Jan-19-22 09:38PM	Marquette Asset Management, LLC Buys Vanguard Total Bond Market ETF, ARK Next Generation ... (GuruFocus.com)
Jan-05-22 08:00AM	Galecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business Officer (GlobeNewswire) -8.76%
Dec-20-21 08:00AM	Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022 (GlobeNewswire)
Dec-13-21 08:00AM	Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial (GlobeNewswire)
Nov-04-21 04:30PM	Galecto Reports Third Quarter Operating and Financial Results (GlobeNewswire)
Nov-02-21 11:26AM	Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting (Benzinga)
08:00AM	Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer (GlobeNewswire)
01:14AM	Penny Stocks to Buy Using Technical Analysis for November 2021 (Investopedia)
Oct-28-21 08:00AM	Galecto Hosting a Key Opinion Leader Webinar on GB1211: A Potential Treatment For Non-Small Cell Lung Cancer (GlobeNewswire)
Oct-26-21 08:00AM	Galecto to Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-15-21 08:30AM	Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference (GlobeNewswire)
Sep-13-21 08:00AM	Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis (GlobeNewswire)
Aug-18-21 09:25AM	Galecto Starts Dosing In Mid-Stage Myelofibrosis Trial (Benzinga)
08:00AM	Galecto Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor GB2064 in Myelofibrosis (the MYLOX-1 Trial) (GlobeNewswire)
Aug-05-21 08:30AM	Galecto Reports Second Quarter Operating and Financial Results (GlobeNewswire)
Jul-28-21 04:31AM	Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely? (Simply Wall St.) +5.19%
Jul-13-21 08:00AM	Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 Trial of GB0139 for Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jun-22-21 12:40PM	Galecto's GB0139 Shows Favorable Safety In COVID-19 Patients, But Plans To Focus On Fibrosis, Cancer Programs (Benzinga)
09:27AM	Galectos GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in Hospitalized COVID-19 Patients (GlobeNewswire)
Jun-10-21 03:31PM	Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times (MarketWatch) +60.00%
Jun-02-21 08:00AM	Galecto Hosting Expert Perspectives Webinar on the Current Myelofibrosis Treatment Landscape and Potential Future Treatments (GlobeNewswire)
May-11-21 08:00AM	Galecto Appoints Garrett Winslow as General Counsel (GlobeNewswire)
May-06-21 08:00AM	Galecto to Present at Upcoming Investor Conferences and Host Myelofibrosis Key Opinion Leader Event (GlobeNewswire)
May-04-21 08:30AM	Galecto Reports First Quarter Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-29-21 05:49AM	Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares? (Simply Wall St.)
Apr-19-21 06:38AM	Galecto (GLTO) Enters Oversold Territory (Zacks)
Apr-15-21 08:00AM	Galectin-3 has a key role in Gastric Cancer (GlobeNewswire)
Mar-29-21 08:30AM	Galecto Reports Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update (GlobeNewswire)
Mar-23-21 10:26AM	UPDATE: Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139 (GlobeNewswire)
08:30AM	Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139 (GlobeNewswire)
Mar-15-21 07:30AM	Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications (GlobeNewswire) -5.61%
Feb-09-21 08:00AM	Galecto to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-29-21 01:33AM	We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth (Simply Wall St.)
Jan-08-21 08:00AM	Galecto Appoints Anne Prener to its Board of Directors (GlobeNewswire)
Jan-04-21 04:01PM	Galecto to Take Part in Two Panel Discussions at the LifeSci Partners 10th Annual Healthcare Corporate Access Event (GlobeNewswire)
Dec-11-20 08:06AM	Galecto Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-30-20 08:00AM	Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing Marked Impact on Several IPF Biomarkers (GlobeNewswire)
Nov-23-20 04:01PM	Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors (GlobeNewswire)
Oct-29-20 01:28PM	Leslies Pops 30%, Allegro Jumps 41% in IPO Debuts (Barrons.com)
Oct-28-20 09:10PM	Galecto Announces Pricing of Initial Public Offering (GlobeNewswire)

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3, lysyl oxidase-like 2, and LOXL2. The company was founded by Ulf Jorgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgard Schambye in 2011 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ORBIMED ADVISORS LLC	10% Owner	Aug 15 '23	Sale	0.75	822,680	617,010	97,204	Aug 17 04:40 PM
ORBIMED ADVISORS LLC	10% Owner	Jul 31 '23	Sale	3.00	209,400	628,200	135,531	Aug 02 05:05 PM
ORBIMED ADVISORS LLC	10% Owner	Jul 25 '23	Sale	2.92	39,200	114,464	162,153	Jul 27 04:28 PM
ORBIMED ADVISORS LLC	10% Owner	Jul 13 '23	Sale	2.40	194,700	467,280	169,953	Jul 17 04:13 PM

Open in Screener

INSP

Inspire Medical Systems Inc

Apr 22 • 04:00PM ET

225.22

Dollar change -4.00
Percentage change -1.75	%

Healthcare • Medical Devices • USA • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

INSP Inspire Medical Systems Inc daily Stock Chart

Held by: VTI VB VXF VBK IHI SCHA IWP IWF VHT IWR

Index	-	P/E	-	EPS (ttm)	-0.74	Insider Own	2.09%	Shs Outstand	30.30M	Perf Week	0.93%
Market Cap	6.82B	Forward P/E	423.90	EPS next Y	0.53	Insider Trans	-11.89%	Shs Float	29.66M	Perf Month	15.36%
Income	-21.15M	PEG	-	EPS next Q	-0.65	Inst Own	102.54%	Short Float	7.01%	Perf Quarter	7.94%
Sales	624.80M	P/S	10.92	EPS this Y	55.08%	Inst Trans	2.55%	Short Ratio	4.08	Perf Half Y	43.41%
Book/sh	19.37	P/B	11.63	EPS next Y	264.26%	ROA	-3.41%	Short Interest	2.08M	Perf Year	-14.96%
Cash/sh	15.19	P/C	14.82	EPS next 5Y	54.10%	ROE	-3.96%	52W Range	123.27 - 330.00	Perf YTD	10.71%
Dividend Est.	-	P/FCF	6690.36	EPS past 5Y	13.57%	ROI	-3.54%	52W High	-31.75%	Beta	1.35
Dividend TTM	-	Quick Ratio	7.17	Sales past 5Y	66.60%	Gross Margin	84.54%	52W Low	82.70%	ATR (14)	11.78
Dividend Ex-Date	-	Current Ratio	7.60	EPS Y/Y TTM	54.94%	Oper. Margin	-6.45%	RSI (14)	53.86	Volatility	6.03% 5.20%
Employees	1011	Debt/Eq	0.04	Sales Y/Y TTM	53.19%	Profit Margin	-3.39%	Recom	1.70	Target Price	255.32
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	368.07%	Payout	-	Rel Volume	1.16	Prev Close	229.22
Sales Surprise	3.08%	EPS Surprise	1015.89%	Sales Q/Q	39.60%	Earnings	May 07 AMC	Avg Volume	510.11K	Price	225.22
SMA20	1.63%	SMA50	10.76%	SMA200	10.37%	Trades		Volume	591,694	Change	-1.75%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-19-24	Initiated	RBC Capital Mkts	Outperform	$285
Mar-19-24	Initiated	Morgan Stanley	Overweight	$250
Feb-06-24	Resumed	KeyBanc Capital Markets	Overweight	$278
Jan-19-24	Initiated	Jefferies	Buy	$245
Jan-02-24	Downgrade	Stifel	Buy → Hold	$210
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$245 → $187
Jul-19-23	Initiated	Robert W. Baird	Outperform	$371
Apr-14-23	Initiated	Mizuho	Buy	$300
Mar-29-23	Initiated	UBS	Buy	$300
Dec-13-22	Upgrade	Goldman	Neutral → Buy	$245 → $308
Dec-13-22	Initiated	KeyBanc Capital Markets	Overweight	$287
Apr-13-22	Initiated	Truist	Buy	$315
Apr-06-22	Initiated	Wolfe Research	Peer Perform	$270
Mar-02-22	Resumed	BofA Securities	Buy	$270
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral
Dec-15-20	Downgrade	Goldman	Buy → Neutral	$162 → $209
Nov-03-20	Upgrade	Oppenheimer	Underperform → Perform
Nov-03-20	Upgrade	BofA Securities	Neutral → Buy	$125 → $155
Sep-22-20	Initiated	JP Morgan	Overweight	$148
Sep-02-20	Initiated	Robert W. Baird	Outperform	$130

Show Previous Ratings

Apr-18-24 12:17PM	Why You Should Add Inspire Medical (INSP) to Your Portfolio (Zacks)
02:14AM	Inspire (INSP) Surges 9.9%: Is This an Indication of Further Gains? (Zacks)
Apr-17-24 08:38AM	Eli Lilly Stock Gains After Study Shows Weight-Loss Drug Helps With Sleep Apnea (The Wall Street Journal) +9.87%
Apr-08-24 05:17AM	Notice to Long-Term Shareholders of Inspire Medical Systems, Inc. (INSP): Grabar Law Office Is Investigating Claims on Your Behalf (Newsfile)
Apr-02-24 08:00AM	Inspire Medical Systems, Inc. to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
07:00PM	Loading…
Mar-27-24 07:00PM	Director Jerry Griffin Sells Shares of Inspire Medical Systems Inc (INSP) (GuruFocus.com)
Mar-21-24 02:31AM	Director Jerry Griffin Sells Shares of Inspire Medical Systems Inc (INSP) (GuruFocus.com)
Mar-18-24 12:01PM	Here's Why You Should Retain Inspire Medical (INSP) Stock Now (Zacks)
Mar-14-24 01:49AM	Director Jerry Griffin Sells Shares of Inspire Medical Systems Inc (INSP) (GuruFocus.com)
Mar-05-24 08:00AM	Inspire Medical Systems, Inc. to Present at the KeyBanc Life Sciences & MedTech Investor Forum (GlobeNewswire)
Feb-13-24 09:02AM	Fundamentals Appear Positive: KeyBanc Suggests 2 MedTech Stocks With up to ~40% Upside (TipRanks)
05:45AM	Investors in Inspire Medical Systems, Inc. Should Contact Levi & Korsinsky Before February 20, 2024 to Discuss Your Rights - INSP (PR Newswire)
Feb-07-24 11:33AM	Q4 2023 Inspire Medical Systems Inc Earnings Call (Thomson Reuters StreetEvents) -10.55%
11:15AM	Inspire Medical Systems, Inc. (NYSE:INSP) Q4 2023 Earnings Call Transcript (Insider Monkey)
10:02AM	Inspire Medical (INSP) Q4 Earnings Top Estimates, Gross Margin Up (Zacks)
06:30PM	Loading…
Feb-06-24 06:30PM	Compared to Estimates, Inspire (INSP) Q4 Earnings: A Look at Key Metrics (Zacks)
05:35PM	Inspire Medical Systems (INSP) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
04:35PM	Inspire Medical Systems Inc Reports Robust Q4 and Full Year 2023 Results (GuruFocus.com)
04:02PM	Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results and Reaffirms 2024 Outlook (GlobeNewswire)
Feb-05-24 08:00AM	Inspire Medical Systems, Inc. Announces Chair Marilyn Carlson Nelson to Retire and Timothy P. Herbert named Chair and Chief Executive Officer (GlobeNewswire)
Feb-04-24 06:56AM	Five Upcoming Class Actions for Investors to Know About (TipRanks)
Feb-01-24 06:55AM	Inspire Medical Systems (INSP) Experienced Volatility in 2023 (Insider Monkey)
Jan-30-24 10:00AM	Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jan-26-24 08:00AM	Inspire Medical Systems, Inc. Announces Jerry C. Griffin, M.D. to Retire from its Board after Sixteen Years of Service (GlobeNewswire)
Jan-24-24 10:15AM	INSPIRE MEDICAL SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Inspire Medical To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Jan-19-24 01:12AM	Here's Why Inspire Medical Systems (INSP) Underperformed the Broader Market (Insider Monkey)
Jan-10-24 10:45AM	INSPIRE MEDICAL SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Inspire Medical To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Jan-09-24 10:39AM	Inspire Medical (INSP) Reports Solid Preliminary Q4 Revenues (Zacks)
08:00AM	Inspire Medical Systems, Inc. to Report Fourth Quarter and Fiscal 2023 Financial Results on February 6, 2024 (GlobeNewswire)
Jan-08-24 08:00AM	Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2023 and Provides Initial 2024 Guidance (GlobeNewswire) +9.15%
01:07PM	Loading…
Jan-05-24 01:07PM	Inspire Medical Systems, Inc. Investors With Large Losses Should Contact Robbins LLP for Information About Their Rights and Remedies Against INSP (Business Wire)
Dec-29-23 09:00AM	3 Reasons to Hold Inspire Medical (INSP) Stock in Your Portfolio (Zacks)
Dec-28-23 08:00AM	Inspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Myriam J. Curet, M.D. to its Board of Directors (GlobeNewswire)
Dec-27-23 06:26PM	15 Best Fast Growth Stocks to Buy Now (Insider Monkey)
05:05AM	Inspire Medical Systems (INSP) Fell on Concerns about Weight Loss Drug (Insider Monkey)
Dec-21-23 10:30PM	Inspire Medical Systems (INSP) Fell on Growing Use of Weight Loss Drug (Insider Monkey) +5.67%
Dec-18-23 08:00AM	Inspire Medical Systems, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-23 11:30AM	Inspire (INSP) Up 16.8% Since Last Earnings Report: Can It Continue? (Zacks) +6.04%
06:08AM	Should You Sell Inspire Medical Systems (INSP)? (Insider Monkey)
Nov-30-23 11:20AM	3 Reasons to Retain Inspire Medical (INSP) Stock for Now (Zacks)
Nov-14-23 03:58PM	FMR LLC Bolsters Portfolio with Inspire Medical Systems Inc Acquisition (GuruFocus.com) +6.25%
08:00AM	Inspire Medical Systems, Inc. to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-11-23 01:34PM	Inspire Medical Systems (INSP) Fell on Fears Relating to Increasing Adoption of Weight Loss Drugs (Insider Monkey)
Nov-09-23 12:41PM	Inspire Medical (INSP) Q3 Earnings Top Estimates, Revenues Lag (Zacks)
Nov-08-23 05:52PM	Inspire Medical Systems, Inc. (NYSE:INSP) Q3 2023 Earnings Call Transcript (Insider Monkey) -19.66%
07:30AM	LifeLens Technologies Expands Executive Leadership Team and Board of Directors (GlobeNewswire)
Nov-07-23 04:03PM	Inspire Medical Systems, Inc. Announces Third Quarter 2023 Financial Results and Updates 2023 Outlook (GlobeNewswire)
Nov-01-23 08:00AM	Inspire Medical Systems, Inc. to Present at the Stifel 2023 Healthcare Conference (GlobeNewswire) +6.23%
Oct-31-23 10:01AM	Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-30-23 04:05PM	11 Best Long-Term Stocks To Buy For High Returns (Insider Monkey)
Oct-23-23 08:00AM	Neuros Medical, Inc. Names David Veino as President and CEO and Expands Board of Directors (PR Newswire)
Oct-19-23 08:55AM	Here's Why Inspire Medical Systems (INSP) Declined in Q3 (Insider Monkey)
Oct-17-23 02:01PM	MedTech Earnings in the Age of Ozempic May Not Be That Bad (Barrons.com)
Oct-11-23 11:40AM	Unveiling Inspire Medical Systems (INSP)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com) -11.10%
Oct-03-23 08:00AM	Inspire Medical Systems, Inc. to Report Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire) -6.33%
Sep-26-23 11:19AM	Here's Why You Should Retain Inspire Medical (INSP) Stock Now (Zacks)
08:00AM	Inspire Medical Systems, Inc. Announces Events at International Surgical Sleep Society and American Academy of Otolaryngology Head and Neck Surgery Meetings (GlobeNewswire)
Sep-22-23 09:05AM	Inspire Medical Systems (INSP) Reported Better-Than-Expected Results in Q2 (Insider Monkey)
Sep-21-23 09:25AM	Weight-Loss Drugs Like Wegovy Are Bad News for These Stocks (Barrons.com)
09:25AM	Weight-Loss Drugs Like Ozempic Are Bad News for These Stocks (Barrons.com)
07:00AM	Tim Herbert Gave A Breath Of Fresh Air To Sleep Apnea Patients (Investor's Business Daily)
01:00AM	Weight-Loss Drugs Are Bad News for Companies That Treat Obesity Complications (Barrons.com)
Sep-20-23 12:39PM	Unlocking the True Worth of Inspire Medical Systems (INSP): A Comprehensive Guide (GuruFocus.com)
Sep-06-23 02:52AM	Do You Think Inspire Medical Systems (INSP) Offers Compelling Opportunity in the Industry? (Insider Monkey)
Aug-23-23 08:00AM	Inspire Medical Systems, Inc. to Present at the Wells Fargo 2023 Healthcare Conference (GlobeNewswire)
Aug-10-23 09:22AM	Is Inspire Medical Systems, Inc. (NYSE:INSP) Potentially Undervalued? (Simply Wall St.)
Aug-02-23 11:25AM	Inspire Medical (INSP) Q2 Earnings & Revenues Top Estimates (Zacks)
Aug-01-23 07:00PM	Compared to Estimates, Inspire (INSP) Q2 Earnings: A Look at Key Metrics (Zacks)
05:25PM	Inspire Medical Systems (INSP) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Inspire Medical Systems, Inc. Announces Second Quarter 2023 Financial Results and Updates 2023 Outlook (GlobeNewswire)
Jul-31-23 09:43AM	MedTech Stocks to Watch for Earnings on Aug 1: ECL, NVRO, INSP (Zacks)
08:00AM	Inspire Medical Systems, Inc. Announces the Addition of Charisse Y. Sparks, M.D. as Chief Medical Officer (GlobeNewswire)
Jul-25-23 11:53AM	Investors Can Rest Easy as ProSomnus Disrupts Obstructive Sleep Apnea Market (IPO-Edge.com)
05:40AM	Does Inspire Medical Systems (INSP) have Long Runway for Growth? (Insider Monkey)
Jul-24-23 08:00AM	Inspire Medical Systems, Inc. Announces Appointment of Carlton Weatherby as Chief Strategy Officer (GlobeNewswire) -5.95%
Jul-05-23 08:00AM	Inspire Medical Systems, Inc. to Report Second Quarter 2023 Financial Results on August 1, 2023 (GlobeNewswire)
Jun-26-23 10:50AM	Inspire Medical (INSP) Hits 52-Week High: What's Aiding It? (Zacks)
Jun-21-23 08:41PM	7 Healthcare Stocks to Make You the Millionaire Next Door (InvestorPlace)
Jun-15-23 02:39PM	Inspire Medical Grows Like Gangbusters With Innovative Sleep Apnea Treatment (Investor's Business Daily)
Jun-14-23 03:00AM	Inspire Medical Systems (INSP) Consolidated in Q1 after Trading at High Valuations (Insider Monkey)
Jun-12-23 09:23AM	Inspire (INSP) Gets FDA Nod for Expanded Indication of AHI (Zacks)
Jun-09-23 09:15AM	Don't Sleep on Inspire Medical Systems as Its Stock Looks Headed Higher (TheStreet.com)
08:00AM	Inspire Medical Systems, Inc. Announces FDA Approval for Apnea Hypopnea Index Indication Expansion and Increased Body Mass Index Labeling (GlobeNewswire)
Jun-05-23 08:00AM	Inspire Medical Systems, Inc. Announces Events at SLEEP 2023, the 37th Annual Meeting of the Associated Professional Sleep Societies (GlobeNewswire)
Jun-01-23 11:31AM	Why Is Inspire (INSP) Up 6.3% Since Last Earnings Report? (Zacks)
09:40AM	Inspire Medical Systems (NYSE:INSP) shareholders have earned a 57% CAGR over the last five years (Simply Wall St.)
May-22-23 11:10AM	3 Reasons to Hold Inspire Medical (INSP) Stock in Your Portfolio (Zacks)
May-18-23 07:35AM	Competition Concerns Impacted Inspire Medical Systems (INSP) (Insider Monkey)
May-16-23 08:00AM	Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2023 Medtech Innovation Spotlight Series (GlobeNewswire)
May-05-23 08:26AM	Inspire Medical Systems, Inc. (NYSE:INSP) Shares Could Be 32% Above Their Intrinsic Value Estimate (Simply Wall St.)
May-04-23 10:05AM	Inspire Medical Systems, Inc. (NYSE:INSP) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-03-23 11:03AM	Q1 2023 Inspire Medical Systems Inc Earnings Call (Thomson Reuters StreetEvents) +6.96%
08:41AM	Inspire Medical (INSP) Q1 Earnings & Revenues Top Estimates (Zacks)
08:00AM	UPDATE - Inspire Medical Systems, Inc. to Present at the BofA Securities Health Care Conference 2023 (GlobeNewswire)
08:00AM	Inspire Medical Systems, Inc. to Present at the RBC Capital Markets 2023 Global Healthcare Conference (GlobeNewswire)
May-02-23 05:15PM	Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Inspire Medical Systems, Inc. Announces First Quarter 2023 Financial Results and Updates 2023 Outlook (GlobeNewswire)
Apr-28-23 11:38AM	AAPL Stock Ramps Higher Ahead Of Quarterly Results. Wall Street Eyes Reports From DraftKings, Arista Networks (Investor's Business Daily)
Apr-26-23 08:00AM	Inspire Medical Systems, Inc. to Present at the BofA Securities Health Care Conference 2023 (GlobeNewswire)
Apr-25-23 11:43AM	11 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)

Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Buchholz Richard	Chief Financial Officer	Apr 17 '24	Sale	230.03	15,000	3,450,450	28,271	Apr 18 04:44 PM
NELSON MARILYN C	Director	Apr 01 '24	Option Exercise	16.00	3,273	52,368	34,338	Apr 02 08:29 PM
Griffin Jerry C	Director	Apr 01 '24	Option Exercise	16.00	296	4,736	10,932	Apr 03 04:55 PM
Herbert Timothy P.	CEO and President	Apr 01 '24	Sale	205.09	40,000	8,203,581	63,658	Apr 03 07:44 PM
Griffin Jerry C	Director	Apr 01 '24	Sale	213.99	32	6,848	10,900	Apr 03 04:55 PM
NELSON MARILYN C	Director	Mar 27 '24	Option Exercise	90.85	3,243	294,633	31,065	Mar 29 04:49 PM
Griffin Jerry C	Director	Mar 25 '24	Option Exercise	16.00	1,000	16,000	11,190	Mar 27 04:01 PM
Griffin Jerry C	Director	Mar 25 '24	Sale	197.81	554	109,587	10,636	Mar 27 04:01 PM
Rondoni John	Chief Technology Officer	Mar 22 '24	Sale	194.40	4,387	852,849	11,270	Mar 26 08:23 PM
Griffin Jerry C	Director	Mar 18 '24	Option Exercise	16.00	1,000	16,000	10,744	Mar 20 05:51 PM
Griffin Jerry C	Director	Mar 18 '24	Sale	193.53	554	107,216	10,190	Mar 20 05:51 PM
Griffin Jerry C	Director	Mar 11 '24	Option Exercise	16.00	1,000	16,000	10,298	Mar 13 09:21 PM
Griffin Jerry C	Director	Mar 11 '24	Sale	198.05	554	109,720	9,744	Mar 13 09:21 PM
Griffin Jerry C	Director	Mar 01 '24	Option Exercise	16.00	1,000	16,000	9,852	Mar 05 05:08 PM
NELSON MARILYN C	Director	Mar 01 '24	Option Exercise	0.94	2,555	2,402	27,822	Mar 05 05:06 PM
Griffin Jerry C	Director	Mar 01 '24	Sale	179.44	554	99,410	8,298	Mar 05 05:08 PM
Rondoni John	Chief Technology Officer	Feb 29 '24	Sale	179.25	8,605	1,542,441	15,657	Mar 04 06:21 PM
Ban Randy	Chief Commercial Officer	Feb 27 '24	Option Exercise	42.15	3,060	128,979	6,089	Feb 27 08:39 PM
Ban Randy	Chief Commercial Officer	Feb 27 '24	Sale	182.01	3,060	556,951	3,029	Feb 27 08:39 PM
Ban Randy	Chief Commercial Officer	Feb 23 '24	Option Exercise	4.11	12,230	50,234	15,259	Feb 27 08:39 PM
Ban Randy	Chief Commercial Officer	Feb 23 '24	Sale	185.37	12,230	2,267,075	3,029	Feb 27 08:39 PM
Rondoni John	Chief Technology Officer	Feb 15 '24	Option Exercise	2.07	8,000	16,560	24,262	Feb 16 04:05 PM
NELSON MARILYN C	Director	Feb 09 '24	Option Exercise	0.94	4,000	3,760	25,267	Feb 13 04:01 PM
Jandrich Steven	VP, Human Resources	Jan 30 '24	Option Exercise	0.94	16,225	15,252	23,096	Jan 31 08:40 PM
NELSON MARILYN C	Director	Oct 17 '23	Option Exercise	0.94	2,000	1,880	21,100	Oct 17 07:52 PM
Herbert Timothy P.	CEO and President	Oct 12 '23	Option Exercise	5.43	208,036	1,128,811	203,691	Oct 16 07:53 PM
Sparks Charisse Y	Chief Medical Officer	Oct 12 '23	Buy	153.50	100	15,350	998	Jan 24 04:32 PM
NELSON MARILYN C	Director	Sep 21 '23	Option Exercise	0.94	2,000	1,880	18,959	Sep 25 06:30 PM
NELSON MARILYN C	Director	Sep 14 '23	Option Exercise	0.94	2,000	1,880	16,959	Sep 18 04:35 PM
Jandrich Steven	VP, Human Resources	Aug 28 '23	Option Exercise	0.94	2,500	2,350	6,871	Aug 30 07:40 PM
Herbert Timothy P.	CEO and President	Aug 23 '23	Option Exercise	70.55	953	67,230	107,784	Aug 28 08:03 AM
NELSON MARILYN C	Director	Aug 21 '23	Option Exercise	0.94	2,000	1,880	14,959	Aug 22 04:05 PM
NELSON MARILYN C	Director	Aug 10 '23	Option Exercise	0.94	2,000	1,880	12,959	Aug 11 04:01 PM
NELSON MARILYN C	Director	Aug 07 '23	Option Exercise	0.94	2,000	1,880	10,959	Aug 09 04:05 PM
NELSON MARILYN C	Director	Aug 04 '23	Option Exercise	0.94	2,000	1,880	8,959	Aug 08 05:00 PM
Griffin Jerry C	Director	Jul 31 '23	Option Exercise	16.00	1,000	16,000	9,381	Aug 01 06:26 PM
Griffin Jerry C	Director	Jul 31 '23	Sale	290.47	529	153,659	8,852	Aug 01 06:26 PM
Griffin Jerry C	Director	Jul 24 '23	Option Exercise	16.00	1,000	16,000	8,910	Jul 26 04:15 PM
NELSON MARILYN C	Director	Jul 24 '23	Option Exercise	0.94	2,000	1,880	6,959	Jul 27 06:29 PM
Griffin Jerry C	Director	Jul 24 '23	Sale	304.99	529	161,340	8,381	Jul 26 04:15 PM
Griffin Jerry C	Director	Jul 17 '23	Option Exercise	16.00	1,000	16,000	8,439	Jul 19 04:50 PM
Griffin Jerry C	Director	Jul 17 '23	Sale	326.84	529	172,898	7,910	Jul 19 04:50 PM
Griffin Jerry C	Director	Jul 10 '23	Option Exercise	16.00	1,000	16,000	7,968	Jul 12 06:00 PM
Griffin Jerry C	Director	Jul 10 '23	Sale	310.42	529	164,212	7,439	Jul 12 06:00 PM
Griffin Jerry C	Director	Jul 03 '23	Option Exercise	16.00	1,000	16,000	7,497	Jul 06 05:26 PM
Griffin Jerry C	Director	Jul 03 '23	Sale	322.09	529	170,386	6,968	Jul 06 05:26 PM
Griffin Jerry C	Director	Jun 26 '23	Option Exercise	16.00	1,000	16,000	7,026	Jun 28 06:21 PM
Griffin Jerry C	Director	Jun 26 '23	Sale	315.87	529	167,095	6,497	Jun 28 06:21 PM
Griffin Jerry C	Director	Jun 20 '23	Option Exercise	16.00	1,000	16,000	6,555	Jun 22 04:07 PM
Griffin Jerry C	Director	Jun 20 '23	Sale	307.64	529	162,742	6,026	Jun 22 04:07 PM
Griffin Jerry C	Director	Jun 12 '23	Option Exercise	16.00	1,000	16,000	6,084	Jun 14 05:56 PM
Griffin Jerry C	Director	Jun 12 '23	Sale	309.03	529	163,477	5,555	Jun 14 05:56 PM
Griffin Jerry C	Director	Jun 05 '23	Option Exercise	16.00	1,000	16,000	5,613	Jun 07 05:57 PM
Griffin Jerry C	Director	Jun 05 '23	Sale	305.69	529	161,710	5,084	Jun 07 05:57 PM
Griffin Jerry C	Director	May 30 '23	Option Exercise	16.00	1,000	16,000	5,142	Jun 01 05:59 PM
Griffin Jerry C	Director	May 30 '23	Sale	294.90	529	156,002	4,613	Jun 01 05:59 PM
Griffin Jerry C	Director	May 22 '23	Option Exercise	16.00	1,000	16,000	4,671	May 24 04:04 PM
Griffin Jerry C	Director	May 22 '23	Sale	307.52	529	162,678	4,142	May 24 04:04 PM
Griffin Jerry C	Director	May 15 '23	Option Exercise	16.00	1,000	16,000	4,200	May 17 08:23 PM
Griffin Jerry C	Director	May 15 '23	Sale	293.91	529	155,478	3,671	May 17 08:23 PM
Jandrich Steven	VP, Human Resources	May 12 '23	Option Exercise	71.00	4,525	321,275	8,896	May 16 05:32 PM
Jandrich Steven	VP, Human Resources	May 12 '23	Sale	292.84	4,525	1,325,107	4,371	May 16 05:32 PM
Jandrich Steven	VP, Human Resources	May 08 '23	Option Exercise	42.15	1,727	72,793	6,098	May 10 08:17 PM
Griffin Jerry C	Director	May 08 '23	Option Exercise	16.00	1,000	16,000	3,729	May 10 08:16 PM
Jandrich Steven	VP, Human Resources	May 08 '23	Sale	280.12	1,727	483,767	4,371	May 10 08:17 PM
Griffin Jerry C	Director	May 08 '23	Sale	280.00	529	148,120	3,200	May 10 08:16 PM
Jandrich Steven	VP, Human Resources	Apr 25 '23	Option Exercise	42.15	8,000	337,200	12,371	May 03 04:35 PM
Jandrich Steven	VP, Human Resources	Apr 25 '23	Sale	271.02	8,000	2,168,164	4,371	May 03 04:35 PM

Open in Screener

FUSN

Fusion Pharmaceuticals Inc

Apr 22 • 04:00PM ET

21.32

Dollar change +0.06
Percentage change 0.28	%

Healthcare • Biotechnology • Canada • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

FUSN Fusion Pharmaceuticals Inc daily Stock Chart

Held by: IBB MNA AVSC FHLC GINN MRGR CANC AVUS BIB IBBQ

Index	-	P/E	-	EPS (ttm)	-1.47	Insider Own	32.99%	Shs Outstand	79.70M	Perf Week	0.19%
Market Cap	1.81B	Forward P/E	-	EPS next Y	-1.67	Insider Trans	0.00%	Shs Float	56.86M	Perf Month	0.57%
Income	-94.90M	PEG	-	EPS next Q	-0.37	Inst Own	49.78%	Short Float	9.14%	Perf Quarter	119.12%
Sales	2.07M	P/S	874.02	EPS this Y	-0.40%	Inst Trans	-2.65%	Short Ratio	2.39	Perf Half Y	405.21%
Book/sh	2.79	P/B	7.64	EPS next Y	-14.62%	ROA	-37.59%	Short Interest	5.20M	Perf Year	514.41%
Cash/sh	2.76	P/C	7.73	EPS next 5Y	-	ROE	-49.34%	52W Range	2.31 - 21.55	Perf YTD	121.85%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-80.83%	ROI	-35.32%	52W High	-1.07%	Beta	-0.67
Dividend TTM	-	Quick Ratio	15.01	Sales past 5Y	8.60%	Gross Margin	-	52W Low	822.94%	ATR (14)	0.39
Dividend Ex-Date	-	Current Ratio	15.01	EPS Y/Y TTM	26.68%	Oper. Margin	-4798.45%	RSI (14)	79.89	Volatility	0.50% 0.69%
Employees	113	Debt/Eq	0.23	Sales Y/Y TTM	41.55%	Profit Margin	-4588.83%	Recom	3.00	Target Price	21.23
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	29.90%	Payout	-	Rel Volume	0.16	Prev Close	21.26
Sales Surprise	-100.00%	EPS Surprise	-15.04%	Sales Q/Q	-100.00%	Earnings	Mar 20 AMC	Avg Volume	2.18M	Price	21.32
SMA20	0.08%	SMA50	34.48%	SMA200	175.41%	Trades		Volume	348,787	Change	0.28%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-27-23	Upgrade	Raymond James	Outperform → Strong Buy	$12 → $15
Sep-29-23	Initiated	Oppenheimer	Outperform	$13
Jun-23-23	Initiated	Raymond James	Outperform	$13
Dec-01-22	Resumed	B. Riley Securities	Buy	$10
Nov-30-22	Initiated	SVB Leerink	Outperform	$6
Sep-16-22	Initiated	Truist	Buy	$10
Jul-06-22	Initiated	William Blair	Outperform
Oct-19-21	Resumed	Morgan Stanley	Overweight	$19
Aug-26-21	Initiated	B. Riley Securities	Buy	$17
Jul-21-20	Initiated	Wedbush	Outperform	$25
Jul-21-20	Initiated	Jefferies	Buy	$25
Jul-21-20	Initiated	Cowen	Outperform

Show Previous Ratings

Apr-17-24 06:15PM	Fusion Pharmaceuticals Inc. (FUSN) Stock Moves -0.09%: What You Should Know (Zacks)
Apr-11-24 05:50PM	Fusion Pharmaceuticals Inc. (FUSN) Flat As Market Gains: What You Should Know (Zacks)
Apr-09-24 04:05PM	Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024 (PR Newswire)
Apr-03-24 08:48AM	Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio (Investopedia)
Mar-25-24 02:52PM	31 European Countries That Offer Citizenship by Descent (Insider Monkey)
09:53PM	Loading…
Mar-20-24 09:53PM	FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace)
05:51PM	15 Countries with the Highest Life Expectancy in Africa (Insider Monkey)
04:05PM	Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates (PR Newswire)
01:21PM	Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca (Zacks)
Mar-19-24 04:28PM	These Stocks Moved the Most Today: Nvidia, AMD, Super Micro, Fusion Pharmaceuticals, Nordstrom, International Paper, Tesla, and More (Barrons.com) +99.06%
04:02PM	Fusion Rockets 99%, As Radiopharmaceuticals Space Sparks On $2 Billion AstraZeneca Takeover (Investor's Business Daily)
02:34PM	Stocks to Watch Tuesday: Super Micro, Fusion Pharmaceuticals, Nvidia, Unilever (The Wall Street Journal)
01:24PM	AstraZeneca acquires Fusion Pharmaceuticals in $2B deal (Yahoo Finance Video)
12:42PM	These Stocks Are Moving the Most Today (Barrons.com)
12:40PM	These Stocks Are Moving the Most Today: Nvidia, AMD, Super Micro, Fusion Pharmaceuticals, Nordstrom, International Paper, Tesla, and More (Barrons.com)
11:15AM	Loading…
11:15AM	AstraZenca is betting $2 billion on next-gen cancer treatments (Quartz)
11:13AM	Fusion Pharmaceuticals Stock Soars. Its Being Acquired by AstraZeneca in $2.4 Billion Deal. (Barrons.com)
10:46AM	Super Micro, XPeng, AstraZeneca: Trending tickers (Yahoo Finance Video)
10:39AM	Heard on the Street: Pharma Goes Radioactive as AstraZeneca Announces Fusion Deal (The Wall Street Journal)
09:03AM	Fusion Pharma Stock Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover (Investor's Business Daily)
08:59AM	AstraZeneca signs agreement to acquire Fusion Pharmaceuticals (Pharmaceutical Business Review)
07:56AM	Why Is Fusion Pharmaceuticals (FUSN) Stock Up 101% Today? (InvestorPlace)
07:38AM	Fusion Pharmaceuticals Is Being Acquired by AstraZeneca in $2.4 Billion Deal. The Stock Is Soaring. (Barrons.com)
04:01AM	AstraZeneca buys into radiopharmaceuticals with $2.4B deal for Fusion Pharma (BioPharma Dive)
03:22AM	UPDATE 3-AstraZeneca bets on next-generation cancer therapy with $2 bln Fusion deal (Reuters)
03:10AM	AstraZeneca bets on next-generation cancer therapy with $2 billion Fusion deal (Reuters)
03:07AM	AstraZeneca to buy Fusion Pharma for $2 billion in cash (Reuters)
03:00AM	Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer (PR Newswire)
Mar-06-24 07:45AM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.71%
Mar-05-24 04:43PM	Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting (PR Newswire)
10:50AM	Loading…
Feb-26-24 10:50AM	Fusion (FUSN) to Report Q4 Earnings: Here's What to Expect (Zacks)
07:45AM	Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences (PR Newswire)
Feb-20-24 06:30AM	These Drug Companies Are Going Nuclear to Fight Cancer (The Wall Street Journal) +10.96%
Feb-19-24 01:31PM	7 Low-Cost Call Options With High-Profit Potential (InvestorPlace)
Feb-16-24 08:45AM	Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy (PR Newswire)
Feb-07-24 07:45AM	Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (PR Newswire) +5.91%
Feb-06-24 04:45PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.48%
Jan-25-24 09:55AM	Wall Street Analysts Believe Fusion Pharmaceuticals Inc. (FUSN) Could Rally 35.09%: Here's is How to Trade (Zacks) +6.28%
Jan-17-24 12:00PM	What Makes Fusion Pharmaceuticals Inc. (FUSN) a New Strong Buy Stock (Zacks)
Jan-16-24 12:00PM	What Makes Fusion Pharmaceuticals Inc. (FUSN) a Strong Momentum Stock: Buy Now? (Zacks) +6.55%
08:22AM	Is it a Good Idea to Buy Fusion Pharmaceuticals (FUSN) Stock Now? (Zacks)
Jan-10-24 08:34AM	How Fusion Pharmaceuticals (FUSN) Stock Stands Out in a Strong Industry (Zacks)
Jan-09-24 06:21PM	Does Fusion Pharmaceuticals Inc. (FUSN) Have the Potential to Rally 47.76% as Wall Street Analysts Expect? (Zacks)
Jan-04-24 04:05PM	Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates (PR Newswire) +6.84%
Dec-28-23 01:11PM	Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday (Zacks) +6.28%
Dec-27-23 02:42PM	Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned (Benzinga) +13.93%
11:02AM	Gracell downgrade, Fusion upgrade: Wall Street's top analyst calls (The Fly)
Dec-13-23 09:55AM	Wall Street Analysts Predict a 149.52% Upside in Fusion Pharmaceuticals Inc. (FUSN): Here's What You Should Know (Zacks)
Dec-08-23 12:00PM	Here's Why Fusion Pharmaceuticals Inc. (FUSN) is a Great Momentum Stock to Buy (Zacks)
Nov-27-23 09:55AM	How Much Upside is Left in Fusion Pharmaceuticals Inc. (FUSN)? Wall Street Analysts Think 162% (Zacks) -6.00%
Nov-16-23 06:45AM	Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical Collaboration (PR Newswire)
06:45AM	BWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator Technology (Business Wire)
Nov-08-23 04:15PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
08:15AM	Fusion Pharmaceuticals to Present at Upcoming Investor Conferences (PR Newswire)
Nov-07-23 08:28AM	Fusion Pharmaceuticals Inc (FUSN) Reports Q3 2023 Financial Results and Clinical Program Updates (GuruFocus.com)
08:25AM	Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates (PR Newswire)
Oct-16-23 07:50AM	Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors (PR Newswire)
Oct-12-23 07:45AM	Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers (PR Newswire)
Sep-06-23 04:25PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -7.61%
Sep-05-23 04:10PM	Fusion Pharmaceuticals to Present at Upcoming September Investor Conferences (PR Newswire)
Aug-14-23 07:55AM	10 Oversold Penny Stocks To Buy (Insider Monkey)
Aug-09-23 04:05PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-08-23 08:15AM	Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Fusion Pharmaceuticals Announces Second Quarter 2023 Financial Results and Clinical Program Updates (PR Newswire)
Aug-05-23 03:30PM	10 Oversold Canadian Stocks To Buy (Insider Monkey)
Jul-06-23 04:05PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.02%
Jun-29-23 10:08AM	One Fusion Pharmaceuticals Insider Raised Stake By 370% In Previous Year (Simply Wall St.)
Jun-26-23 08:05AM	Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R (PR Newswire)
Jun-16-23 08:05AM	Fusion Pharmaceuticals to Present at the TD Cowen Radiopharmaceutical Innovation Summit (PR Newswire)
Jun-07-23 07:35AM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-31-23 04:10PM	Fusion Pharmaceuticals to Present at the Jefferies Healthcare Conference (PR Newswire) +18.06%
10:58AM	These 2 Strong Buy Penny Stocks Could Surge 200% (or More), Says Wedbush (TipRanks)
May-12-23 06:09AM	Fusion Pharmaceuticals First Quarter 2023 Earnings: Misses Expectations (Simply Wall St.)
May-11-23 07:15AM	Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates (PR Newswire)
May-10-23 08:34AM	Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) has caught the attention of institutional investors who hold a sizeable 34% stake (Simply Wall St.) +7.45%
May-09-23 07:45AM	Fusion Pharmaceuticals to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day (PR Newswire)
May-02-23 04:00PM	Fusion Pharmaceuticals Announces Opening of Radiopharmaceutical Manufacturing Facility to Produce Targeted Alpha Therapies for Cancer (PR Newswire) -7.56%
Apr-20-23 04:15PM	Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference (PR Newswire) -8.92%
Apr-19-23 04:25PM	Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2059 and Leading Targeted Alpha Therapy Platform at AACR Annual Meeting (PR Newswire) -7.07%
Apr-13-23 09:47AM	Fusion (FUSN) to Begin Clinical Study on Targeted Alpha Therapy (Zacks)
Apr-12-23 04:05PM	Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy (PR Newswire)
Apr-05-23 04:10PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-20-23 04:05PM	Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1 (PR Newswire)
Mar-16-23 08:45AM	Fusion Pharmaceuticals Inc. (FUSN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates (PR Newswire)
Mar-08-23 04:35PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-02-23 04:35PM	Fusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare Conference (PR Newswire) +6.11%
Feb-14-23 07:59AM	Fusion Pharma Raises $60M To Fund Acquisition Of Prostate Cancer-Targeted Radiopharmaceutical (Benzinga) +22.10%
Feb-13-23 04:05PM	Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer (PR Newswire) +5.23%
08:05AM	Fusion Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference (PR Newswire)
Feb-07-23 04:10PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-20-23 08:33AM	A Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) insider increased their holdings by 370% last year (Simply Wall St.) -5.32%
Jan-06-23 07:45AM	Fusion Pharmaceuticals Reports Progress and Provides Recent Corporate Highlights (PR Newswire) +5.87%
Jan-05-23 05:00PM	Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies (PR Newswire) +8.07%
Jan-04-23 04:35PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +8.44%
Dec-22-22 09:52AM	2 Strong Buy Penny Stocks That Could Go Boom (TipRanks) +21.45%
Dec-07-22 04:15PM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-09-22 07:10AM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-08-22 08:25AM	Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +8.59%

Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. The company was founded by John Vaillant in 2014 and is headquartered in Hamilton, Canada.

Open in Screener

NXTC

Nextcure Inc

Apr 22 • 04:00PM ET

1.61

Dollar change +0.01
Percentage change 0.62	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC DFAS

Index	-	P/E	-	EPS (ttm)	-2.25	Insider Own	24.39%	Shs Outstand	27.90M	Perf Week	-3.59%
Market Cap	45.03M	Forward P/E	-	EPS next Y	-1.69	Insider Trans	0.00%	Shs Float	21.15M	Perf Month	-4.17%
Income	-62.72M	PEG	-	EPS next Q	-0.46	Inst Own	36.23%	Short Float	4.70%	Perf Quarter	42.48%
Sales	0.00M	P/S	-	EPS this Y	25.78%	Inst Trans	4.92%	Short Ratio	3.58	Perf Half Y	22.90%
Book/sh	4.10	P/B	0.39	EPS next Y	-0.90%	ROA	-39.81%	Short Interest	0.99M	Perf Year	3.87%
Cash/sh	3.87	P/C	0.42	EPS next 5Y	-	ROE	-44.49%	52W Range	0.98 - 2.57	Perf YTD	41.23%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-17.56%	ROI	-52.11%	52W High	-37.35%	Beta	0.49
Dividend TTM	-	Quick Ratio	16.38	Sales past 5Y	30.52%	Gross Margin	-	52W Low	64.29%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	16.38	EPS Y/Y TTM	16.35%	Oper. Margin	0.00%	RSI (14)	42.08	Volatility	8.93% 12.43%
Employees	82	Debt/Eq	0.06	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.40	Target Price	5.00
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	16.78%	Payout	-	Rel Volume	0.37	Prev Close	1.60
Sales Surprise	-	EPS Surprise	4.04%	Sales Q/Q	-	Earnings	Mar 21 BMO	Avg Volume	277.49K	Price	1.61
SMA20	-17.83%	SMA50	-5.90%	SMA200	11.30%	Trades		Volume	101,385	Change	0.62%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-22	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-22	Initiated	Ladenburg Thalmann	Buy	$16
Mar-05-21	Upgrade	Truist	Hold → Buy	$19
Jan-15-21	Downgrade	BofA Securities	Neutral → Underperform	$10
Jul-16-20	Upgrade	The Benchmark Company	Hold → Buy	$17
Jul-13-20	Downgrade	SunTrust	Buy → Hold
Jul-13-20	Downgrade	ROTH Capital	Buy → Neutral
Jun-01-20	Downgrade	The Benchmark Company	Buy → Hold
Jun-01-20	Downgrade	BofA/Merrill	Buy → Neutral	$62 → $40
May-26-20	Initiated	JMP Securities	Mkt Outperform	$55
Mar-24-20	Initiated	The Benchmark Company	Buy	$55
Mar-02-20	Initiated	ROTH Capital	Buy	$80
Jan-13-20	Initiated	SunTrust	Buy	$78
Dec-05-19	Initiated	Needham	Buy
Nov-26-19	Initiated	BTIG Research	Buy	$61
Jul-09-19	Initiated	BofA/Merrill	Buy	$25
Jun-03-19	Initiated	Piper Jaffray	Overweight	$26
Jun-03-19	Initiated	Morgan Stanley	Overweight	$25

Show Previous Ratings

Apr-08-24 07:00AM	NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024 (GlobeNewswire) -5.96%
Apr-04-24 07:05AM	NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board (GlobeNewswire) -10.00%
Apr-02-24 07:00AM	NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +7.79%
Mar-23-24 06:00AM	Wall Streets Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich (InvestorPlace)
Mar-21-24 10:54PM	NXTC Stock Earnings: NextCure Beats EPS for Q4 2023 (InvestorPlace) +19.15%
11:22AM	Loading…
11:22AM	NextCure to lay off 37% of staff, dial back research plans (BioPharma Dive)
08:55AM	NextCure Provides Business Update and Reports Full Year 2023 Financial Results (GlobeNewswire)
Mar-05-24 08:05AM	NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances (GlobeNewswire)
Jan-18-24 04:05PM	NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders (GlobeNewswire)
Dec-25-23 09:55AM	Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing (Zacks)
Dec-21-23 07:05AM	NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury (GlobeNewswire)
Dec-15-23 11:23AM	NextCure (NXTC) Down on Shelving Plans to Develop Candidate (Zacks) -5.13%
Dec-14-23 09:14AM	NextCure jettisons monoclonal antibody to focus on ADC aimed at same target (FierceBiotech.com) -19.31%
06:45AM	NextCure Provides Year-End Clinical Pipeline Updates (GlobeNewswire)
Nov-20-23 07:00AM	NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
04:05PM	Loading…
Nov-15-23 04:05PM	NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML (GlobeNewswire) +5.93%
Nov-07-23 12:00PM	All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy (Zacks)
Nov-02-23 06:07PM	NextCure Inc (NXTC) Reports Q3 2023 Financial Results (GuruFocus.com) +9.35%
04:05PM	NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-17-23 08:05AM	Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI) (GlobeNewswire)
Sep-26-23 04:05PM	NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimers Disease (GlobeNewswire)
Sep-12-23 08:05AM	A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC (GlobeNewswire)
Sep-07-23 04:05PM	NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen (GlobeNewswire)
Sep-05-23 04:05PM	Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease (GlobeNewswire)
Aug-31-23 07:00AM	NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jun-21-23 04:05PM	NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting (GlobeNewswire)
May-11-23 01:58PM	Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? (Simply Wall St.)
May-09-23 07:00AM	NextCure to Present at the JMP Securities Life Sciences Conference (GlobeNewswire) +7.41%
May-04-23 04:05PM	NextCure Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
07:00AM	Loading…
Apr-11-23 07:00AM	NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-02-23 04:05PM	NextCure Provides Business Update and Reports Full Year 2022 Financial Results (GlobeNewswire)
Feb-07-23 07:00AM	NextCure to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Dec-02-22 10:59AM	Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-22-22 08:00AM	NextCure to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-16-22 08:09AM	NextCure, LegoChem Biosciences Ink Collaborative Pact For Antibody Drug Conjugates (Benzinga) -6.02%
Nov-15-22 04:30PM	NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates (GlobeNewswire)
Nov-07-22 08:05AM	NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) -13.64%
Nov-03-22 04:15PM	NextCure Provides Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
09:15AM	NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-27-22 04:05PM	NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board (GlobeNewswire)
Oct-05-22 12:00PM	NextCure, Inc. (NXTC) Moves to Buy: Rationale Behind the Upgrade (Zacks)
08:15AM	NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Oct-04-22 04:05PM	NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors (GlobeNewswire) +9.42%
Sep-22-22 08:00AM	NextCure to Present at the Ladenburg Thalmann Healthcare Conference (GlobeNewswire) -12.64%
Aug-22-22 06:23AM	With 37% ownership, NextCure, Inc. (NASDAQ:NXTC) has piqued the interest of institutional investors (Simply Wall St.) -5.45%
Aug-04-22 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-06-22 08:00AM	NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation (GlobeNewswire)
Jun-27-22 08:00AM	NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM (GlobeNewswire)
Jun-25-22 10:26AM	We're Hopeful That NextCure (NASDAQ:NXTC) Will Use Its Cash Wisely (Simply Wall St.)
Jun-22-22 08:00AM	Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting (GlobeNewswire)
Jun-08-22 08:00AM	NextCure to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
May-11-22 08:17AM	NextCure, Inc.'s (NASDAQ:NXTC) Intrinsic Value Is Potentially 34% Above Its Share Price (Simply Wall St.)
May-05-22 04:05PM	NextCure Provides Business Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-03-22 08:00AM	NextCure to Present at the BofA Securities 2022 Healthcare Conference (GlobeNewswire)
Apr-19-22 07:30AM	NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation (GlobeNewswire)
Apr-05-22 08:00AM	NextCure to Present at 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-15-22 06:21AM	What Type Of Shareholders Own The Most Number of NextCure, Inc. (NASDAQ:NXTC) Shares? (Simply Wall St.)
Mar-03-22 04:05PM	NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Feb-08-22 08:00AM	NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Dec-13-21 08:05AM	NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-30-21 08:00AM	NextCure to Present at The JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-22-21 08:00AM	NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-13-21 02:00PM	NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Nov-04-21 04:05PM	NextCure Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
09:15AM	NextCure Announces Presentations on Targets in Development by Collaborators at American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-01-21 08:00AM	NextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021 (GlobeNewswire)
Oct-19-21 08:05AM	NextCure Announces Three New Members of its Scientific Advisory Board (GlobeNewswire)
Oct-07-21 04:05PM	NextCure Announces Publication of Preclinical Data for NC410 (GlobeNewswire)
Oct-04-21 08:05AM	NextCure Announces New Appointments to its Board of Directors (GlobeNewswire)
Oct-01-21 08:45AM	NextCure to Give Three Presentations at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) +12.17%
Sep-29-21 10:41AM	What Is The Ownership Structure Like For NextCure, Inc. (NASDAQ:NXTC)? (Simply Wall St.)
Sep-07-21 07:00AM	NextCure to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Sep-02-21 07:00AM	NextCure to Present at the 19th Annual Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-05-21 04:05PM	NextCure Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-06-21 04:05PM	NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors (GlobeNewswire)
Jun-22-21 06:34AM	NextCure's Immunomedicine NC410 Shows Promising Anti-Cancer Activity In Preclinical Studies (Benzinga)
Jun-21-21 04:05PM	NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410 (GlobeNewswire)
Jun-10-21 04:10PM	NextCure to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
May-19-21 06:05PM	NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-06-21 05:15PM	NextCure Reports First Quarter 2021 Financial Results (GlobeNewswire)
May-05-21 04:10PM	NextCure to Present at the BofA Securities 2021 Virtual Health Care Conference (GlobeNewswire)
Apr-28-21 04:10PM	NextCure to Present at the 7th Annual Truist Securities Life Sciences Summit (GlobeNewswire)
Apr-10-21 08:30AM	NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021 (GlobeNewswire)
Apr-07-21 04:05PM	NextCure to Present at the 20th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-02-21 04:45AM	Are Institutions Heavily Invested In NextCure, Inc.'s (NASDAQ:NXTC) Shares? (Simply Wall St.)
Mar-04-21 04:05PM	NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results (GlobeNewswire)
Mar-02-21 04:05PM	REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021 (GlobeNewswire)
Feb-26-21 04:15PM	NextCure to Host Virtual R&D Update Event on March 4, 2021 (GlobeNewswire)
Feb-11-21 05:58PM	LONG-TERM INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses to Contact the Firm (Newsfile)
Feb-01-21 06:31AM	NextCure's (NASDAQ:NXTC) Stock Price Has Reduced 73% In The Past Year (Simply Wall St.)
Jan-28-21 11:00AM	LONG-TERM SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses to Contact the Firm (PR Newswire)
Jan-27-21 08:33AM	LONG-TERM SHAREHOLDER REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses to Contact the Firm (Business Wire) -6.97%
Jan-14-21 04:05PM	Dr. Han Myint Appointed as NextCures Chief Medical Officer (GlobeNewswire) +8.11%
Dec-18-20 01:48PM	LONG-TERM SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses to Contact the Firm (Business Wire)
Dec-17-20 07:05AM	NextCure Provides Updates on NC318 Clinical Program (GlobeNewswire) -10.14%
Dec-14-20 08:35AM	NextCure (NXTC) in Focus: Stock Moves 7.6% Higher (Zacks) +5.58%
07:07AM	Is NXTC A Good Stock To Buy Now? (Insider Monkey)
Nov-28-20 11:50PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NextCure, Inc. - NXTC (ACCESSWIRE)
Nov-26-20 03:24AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NextCure, Inc. - NXTC (GlobeNewswire)

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

GLTO

Galecto Inc

INSP

Inspire Medical Systems Inc

FUSN

Fusion Pharmaceuticals Inc

NXTC

Nextcure Inc

Upgrade your FINVIZ experience